Table 2 Outcomes in the studies included in the meta-analysis
First Author [Reference No.] | Outcomes, n° (%) of patients in Peg-IFN α-2a/α-2b group | ||||||
|---|---|---|---|---|---|---|---|
RVR | EVR | ETR | SVR | Discontinuation of therapy for adverse events in patients with genotype 1 all genotypes | Peg-IFN reduction for adverse events in patients with all genotypes | ||
Yenice [16] # | 28(75.7)/27(73) | 18(48.6)/13(35.1) | 3 (7.5)/3 (7.5) | 3 (7.5)/3 (7.5) | |||
Di Bisceglie [17] § | 14(7.4)/22(11.5) | 74(39.1)/84(43.9) | |||||
Escudero [18] † | 15(25.4)/10(17.2) | 33(55.9)/29(50) | 12(20.3)/7(12.1) | 30(50.8)/27(46.6) | 12(13.1)/10(10.8) | 8(8.7)/7(7.6) | |
McHutchison [19] $ | 123(11.9)/116(11.4) | 466(45)/407(39.9) | 667(64.4)/542(53.2) | 423(40.9)/406(39.8) | 135(13)/129(12.6) | 135(13)/129(12.6) | 264(25.5)/254(24.9) |
Ascione [20] § | 51(54.8)/37(39.8) | 3 (3.2)/13 (14) | 4(2.5)/22(13.7) | ||||
Lee [21] ^ | 16(76.2)/12(75) | 16(76.2)/13(81.3) | 8(38)/10(62.5) | 8(10.1)/5(10.6) | |||
Rumi [22] ç | 34(37)/26(30) | 60(66)/40(46) | 59(65)/38(44) | 44(48)/28(32) | 16(7.5)/17(7.7) | 22(10.3)/14(6.3) | |